OClawVPS.com
Sana Biotechnology, Inc.
Edit

Sana Biotechnology, Inc.

http://www.sana.com/
Last activity: 11.10.2025
Active
Categories: BioTechBodyBuildingCauseDeliveryHealthTechHumanITManufacturingPublic
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy.

Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders.

Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.
Website visits
20.8K /mo.
Mentions
56
Location: United States, Washington, Seattle
Employees: 201-500
Total raised: $2.79B
Valuation: $6.5B
Founded date: 2018

Investors 9

Funding Rounds 4

DateSeriesAmountInvestors
04.02.2021IPO$587.5M-
23.10.2020-$700M-
25.06.2020-$700M-
07.01.2019-$800M-

Mentions in press and media 56

DateTitleDescription
11.10.2025U.S. founders are ‘shameless’ with feedback and Europe’s should do the same: OpenAI’s startup bossIn the latest comparison between American and European founders, OpenAI’s startup boss admitted that the Americans are “almost shameless” when it comes to making demands and giving feedback to the AI giant. Laura Modiano, who heads up OpenA...
03.10.2025U.S. model upgrades are pushing AI startups to move fast – it’s unclear if Europe can keep upEurope’s opportunity in AI lies with putting it to use. But the pace of development is still being set by AI model developers like OpenAI and Anthropic. Questions around whether the bloc can compete still linger. Artificial intelligence com...
26.09.2025Light Secures $30M to Revolutionize Enterprise Finance with AI-Native PlatformLight, a Copenhagen-born FinTech, raised $30 million in Series A funding. This investment propels its AI-native finance platform. Light targets hypergrowth companies. It offers a complete ERP replacement. The platform processes millions of ...
26.09.2025Sweden’s Redpine launches with €1.1 million backing to reduce AI hallucinations through licensed dataAfter a year in stealth, Stockholm-based company Redpine announces €1.1 million in funding and the launch of their platform to give AI builders and agents high-quality, licensed data. The round saw participation from prominent angel investo...
25.09.2025Light raises €25 million to replace legacy finance systems with AI-native platformLight, an AI-native finance platform out of Copenhagen that processes 280 million records in under a second, today announced €25 million in Series A funding to expand to the US, triple its engineering team, and further build out the deploym...
19.09.2025Nothing raises $200M, First Round of Speakers for the Tech.eu Summit London 2026, and Google pledges £5BN UK AI investmentThis week, we tracked more than 80 tech funding deals worth over €1.3 billion, and over 20 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most ...
19.09.20252025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma TreatmentSHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 19, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovati...
17.09.2025Workday acquires Swedish startup Sana in a €928 million AI dealWorkday, Inc., the American enterprise AI platform for managing people, money, and agents, has entered into a definitive agreement to acquire Stockholm’s Sana, an AI company building the next generation of enterprise knowledge tools, for ap...
16.09.2025Workday to acquire Sana for $1.1 billionWorkday, the enterprise AI platform for managing people, money, and agents, has entered into a definitive agreement to acquire Sana, a Stockholm AI company building the next generation of enterprise knowledge tools. Since its founding in 20...
16.09.2025Американская компания Workday покупает стартап по искусственному интеллекту Sana за $1,1 млрдКомпания Workday во вторник объявила о планах приобрести фирму по разработке искусственного интеллекта Sana примерно за $1,1 млрд, чтобы повысить спрос, интегрируя возможности ИИ в свои продукты для управления персоналом. Эта сделка стала ч...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In